Page last updated: 2024-08-25

sofosbuvir and Hyperlipoproteinemia Type II

sofosbuvir has been researched along with Hyperlipoproteinemia Type II in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bruckert, E; Caron, J; Dubart-Kupperschmitt, A; Fourrier, A; Gómez-Lechón, MJ; Heslan, JM; Luce, E; Nguyen, TH; Pène, V; Rosenberg, AR; Saheb, S; Tolosa, L; Villaret, M; Weber, A1

Other Studies

1 other study(ies) available for sofosbuvir and Hyperlipoproteinemia Type II

ArticleYear
Low-density lipoprotein receptor-deficient hepatocytes differentiated from induced pluripotent stem cells allow familial hypercholesterolemia modeling, CRISPR/Cas-mediated genetic correction, and productive hepatitis C virus infection.
    Stem cell research & therapy, 2019, 07-29, Volume: 10, Issue:1

    Topics: Antiviral Agents; Apolipoprotein A-II; Cell Differentiation; Cholesterol; CRISPR-Cas Systems; Gene Editing; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Hyperlipoproteinemia Type II; Induced Pluripotent Stem Cells; Phenotype; Plasmids; Promoter Regions, Genetic; Proprotein Convertase 9; Receptors, LDL; Sofosbuvir; Sterol Regulatory Element Binding Protein 2

2019